Erin E. Cawston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erin E. Cawston has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Joanna M. Williams
Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand
2 shared publications - John C. Dalrymple-Alford
Te Kura Mahi ā‐Hirikapo School of Psychology, Speech and Hearing University of Canterbury Christchurch New Zealand
2 shared publications - Leon Griner
University of Auckland, Auckland, Auckland New Zealand
2 shared publications - Lynette J. Tippett
School of Psychology, The University of Auckland, Auckland New Zealand
2 shared publications - Tim J. Anderson
New Zealand Brain Research Institute Christchurch New Zealand
2 shared publications - Tracy R. Melzer
New Zealand Brain Research Institute, Christchurch, New Zealand
2 shared publications
Latest Publications
- Open Access
Examining the relationship between plasma pTau181 and cognitive decline, structural brain integrity, and biological ageing in midlife
INTRODUCTION Although plasma pTau181 has been shown to accurately discriminate patients with Alzheimer’s disease from healthy older adults, its utility as a preclinical biomarker in middle-aged community-based cohorts is unclear. METHODS Participants were members of the Dunedin Multidisciplinary Health and Development Study, a longitudinal study of 1037 people born in New Zealand in 1972-1973. Plasma pTau181, MRI-based brain structure, and DunedinPACE (an epigenetic biomarker of biological ageing) were measured at age 45; cognition was measured in childhood and age 45. RESULTS We observed a wide range of pTau181 concentrations in our same-aged sample (n=856; M=13.6pg/mL, SD=9.1pg/mL). Males had significantly higher pTau181 concentrations than females. No statistically significant associations were observed with cognitive decline, lower structural brain integrity, or accelerated biological ageing. DISCUSSION In this midlife cohort, wide variation in pTau181 concentrations was present by age 45, but was not associated with patterns of AD-risk in cognition, brain structure, or biological ageing. Systematic review Authors reviewed the literature using PubMed and Web of Science databases. While research on plasma biomarkers of AD has largely focused on older people with mild cognitive impairment or AD, there are few studies of plasma biomarkers among general middle-aged populations. Given the potential utility of plasma biomarkers of AD such as pTau181 in early screening for disease risk, examining the concentrations of pTau181 among a younger cohort free of dementia is important for possible future clinical implementation. Interpretation Plasma pTau181 concentrations varied widely among our same-aged sample, yet higher pTau181 was not associated with cognitive decline, lower MRI-estimated structural brain integrity, or accelerated biological ageing. These findings indicate that variability in pTau181 exists in middle-age, but independently of other AD risk factors. Future directions Understanding how variability in pTau181 concentrations in midlife may predict later AD and to what extent this is distinct from other risk factors is important for shaping the translational pathway from lab to clinic.
Open AccessExamining the relationship between plasma pTau181 and cognitive decline, structural brain integrity, and biological ageing in midlife
INTRODUCTION Although plasma pTau181 has been shown to accurately discriminate patients with Alzheimer’s disease from healthy older adults, its utility as a preclinical biomarker in middle-aged community-based cohorts is unclear. METHODS Participants were members of the Dunedin Multidisciplinary Health and Development Study, a longitudinal study of 1037 people born in New Zealand in 1972-1973. Plasma pTau181, MRI-based brain structure, and DunedinPACE (an epigenetic biomarker of biological ageing) were measured at age 45; cognition was measured in childhood and age 45. RESULTS We observed a wide range of pTau181 concentrations in our same-aged sample (n=856; M=13.6pg/mL, SD=9.1pg/mL). Males had significantly higher pTau181 concentrations than females. No statistically significant associations were observed with cognitive decline, lower structural brain integrity, or accelerated biological ageing. DISCUSSION In this midlife cohort, wide variation in pTau181 concentrations was present by age 45, but was not associated with patterns of AD-risk in cognition, brain structure, or biological ageing. Systematic review Authors reviewed the literature using PubMed and Web of Science databases. While research on plasma biomarkers of AD has largely focused on older people with mild cognitive impairment or AD, there are few studies of plasma biomarkers among general middle-aged populations. Given the potential utility of plasma biomarkers of AD such as pTau181 in early screening for disease risk, examining the concentrations of pTau181 among a younger cohort free of dementia is important for possible future clinical implementation. Interpretation Plasma pTau181 concentrations varied widely among our same-aged sample, yet higher pTau181 was not associated with cognitive decline, lower MRI-estimated structural brain integrity, or accelerated biological ageing. These findings indicate that variability in pTau181 exists in middle-age, but independently of other AD risk factors. Future directions Understanding how variability in pTau181 concentrations in midlife may predict later AD and to what extent this is distinct from other risk factors is important for shaping the translational pathway from lab to clinic.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Plasma biomarkers across the Alzheimer’s disease continuum in the New Zealand‐Dementia Prevention Research Clinics
Background: Advances in ultra‐sensitive immunoassay methods, like Single molecule array (Simoa) technology, show that Alzheimer’s disease (AD) neuropathology can be detected in blood at the earliest stages of AD. This study compared cross‐sectional biomarker profiles for participants from the New Zealand‐Dementia Prevention Research Clinics (NZ‐DPRCs) who spanned the continuum from healthy older adults to a clinical diagnosis of AD.Method: Blood plasma samples were obtained from 253 NZ‐DPRC participants (aged 55 to 87) from their baseline assessment. Participants were classified as cognitively normal adults (CN, n = 34), subjective cognitive decline (SCD, n = 64), non‐amnestic mild cognitive impairment (single and multi‐domain, non‐aMCI, n = 23), amnestic MCI (single and multi‐domain, aMCI, n = 105), and AD (n = 27). Six plasma biomarkers were selected for quantification by the HD‐X Simoa analyser (Quanterix, Billerica, MA; University of Gothenburg, Sweden): AD biomarkers amyloid‐beta peptides (Aß1‐40; Aß1‐42) and phosphorylated tau species (p‐tau181; p‐tau231); neurofilament light (NfL), for general neuronal damage; and glial fibrillary acidic protein (GFAP), for astrocyte activation. Clinical, imaging and genetic demographic data were assessed in relation to the plasma biomarkers.Result: Plasma biomarkers across the five groups (figure 1) were assessed by linear regression adjusted for age and sex. P‐tau181, p‐tau231, GFAP and NfL were natural log‐transformed to approximate normality and improve homogeneity of variance. Biomarkers p‐tau181, p‐tau231, GFAP, NfL, Aß1‐42/Aß1‐40 ratio and Aß1‐42, all showed group effects (P < 0.05; Aß1‐40, pP < 0.05); p‐tau181 for AD vs CN and SCD (P < 0.05); p‐tau231 for AD vs non‐aMCI (P < 0.05); Aß1‐42 for aMCI vs CN and SCD (P < 0.05); Aß1‐42/Aß1‐40 ratio for SCD vs aMCI (P < 0.05). ROC analysis will be reported for the diagnostic accuracy of these blood analytes.Conclusion: Simoa‐quantitated blood biomarkers in the NZ‐DPRC cohort differentiates clinical groups spanning the AD continuum cross‐sectionally.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S14)
Open AccessPlasma biomarkers across the Alzheimer’s disease continuum in the New Zealand‐Dementia Prevention Research Clinics
Background: Advances in ultra‐sensitive immunoassay methods, like Single molecule array (Simoa) technology, show that Alzheimer’s disease (AD) neuropathology can be detected in blood at the earliest stages of AD. This study compared cross‐sectional biomarker profiles for participants from the New Zealand‐Dementia Prevention Research Clinics (NZ‐DPRCs) who spanned the continuum from healthy older adults to a clinical diagnosis of AD.Method: Blood plasma samples were obtained from 253 NZ‐DPRC participants (aged 55 to 87) from their baseline assessment. Participants were classified as cognitively normal adults (CN, n = 34), subjective cognitive decline (SCD, n = 64), non‐amnestic mild cognitive impairment (single and multi‐domain, non‐aMCI, n = 23), amnestic MCI (single and multi‐domain, aMCI, n = 105), and AD (n = 27). Six plasma biomarkers were selected for quantification by the HD‐X Simoa analyser (Quanterix, Billerica, MA; University of Gothenburg, Sweden): AD biomarkers amyloid‐beta peptides (Aß1‐40; Aß1‐42) and phosphorylated tau species (p‐tau181; p‐tau231); neurofilament light (NfL), for general neuronal damage; and glial fibrillary acidic protein (GFAP), for astrocyte activation. Clinical, imaging and genetic demographic data were assessed in relation to the plasma biomarkers.Result: Plasma biomarkers across the five groups (figure 1) were assessed by linear regression adjusted for age and sex. P‐tau181, p‐tau231, GFAP and NfL were natural log‐transformed to approximate normality and improve homogeneity of variance. Biomarkers p‐tau181, p‐tau231, GFAP, NfL, Aß1‐42/Aß1‐40 ratio and Aß1‐42, all showed group effects (P < 0.05; Aß1‐40, pP < 0.05); p‐tau181 for AD vs CN and SCD (P < 0.05); p‐tau231 for AD vs non‐aMCI (P < 0.05); Aß1‐42 for aMCI vs CN and SCD (P < 0.05); Aß1‐42/Aß1‐40 ratio for SCD vs aMCI (P < 0.05). ROC analysis will be reported for the diagnostic accuracy of these blood analytes.Conclusion: Simoa‐quantitated blood biomarkers in the NZ‐DPRC cohort differentiates clinical groups spanning the AD continuum cross‐sectionally.
- 24 August 2022
- Published by Wiley in Journal of the Royal Society of New Zealand
- Vol. 53 (4) , 489-510
Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand
Aotearoa New Zealand's population is ageing. Increasing life expectancy is accompanied by increases in prevalence of Alzheimer's Disease (AD) and ageing‐related disorders. The multicentre Dementia Prevention Research Clinic longitudinal study aims to improve understanding of AD and dementia in Aotearoa, in order to develop interventions that delay or prevent progression to dementia. Comprising research clinics in Auckland, Christchurch and Dunedin, this multi‐disciplinary study involves community participants who undergo biennial investigations informed by international protocols and best practice: clinical, neuropsychological, neuroimaging, lifestyle evaluations, APOE genotyping, blood collection and processing. A key research objective is to identify a ‘biomarker signature’ that predicts progression from mild cognitive impairment to AD. Candidate biomarkers include: blood proteins and microRNAs, genetic, neuroimaging and neuropsychological markers, health, cultural, lifestyle, sensory and psychosocial factors. We are examining a range of mechanisms underlying the progression of AD pathology (e.g. faulty blood–brain barrier, excess parenchymal iron, vascular dysregulation). This paper will outline key aspects of the Dementia Prevention Research Clinic's research, provide an overview of data collection, and a summary of 266 participants recruited to date. The national outreach of the clinics is a strength; the heart of the Dementia Prevention Research Clinics are its people.
- 24 August 2022
- Published by Wiley in Journal of the Royal Society of New Zealand
- Vol. 53 (4) , 489-510
Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand
Aotearoa New Zealand's population is ageing. Increasing life expectancy is accompanied by increases in prevalence of Alzheimer's Disease (AD) and ageing‐related disorders. The multicentre Dementia Prevention Research Clinic longitudinal study aims to improve understanding of AD and dementia in Aotearoa, in order to develop interventions that delay or prevent progression to dementia. Comprising research clinics in Auckland, Christchurch and Dunedin, this multi‐disciplinary study involves community participants who undergo biennial investigations informed by international protocols and best practice: clinical, neuropsychological, neuroimaging, lifestyle evaluations, APOE genotyping, blood collection and processing. A key research objective is to identify a ‘biomarker signature’ that predicts progression from mild cognitive impairment to AD. Candidate biomarkers include: blood proteins and microRNAs, genetic, neuroimaging and neuropsychological markers, health, cultural, lifestyle, sensory and psychosocial factors. We are examining a range of mechanisms underlying the progression of AD pathology (e.g. faulty blood–brain barrier, excess parenchymal iron, vascular dysregulation). This paper will outline key aspects of the Dementia Prevention Research Clinic's research, provide an overview of data collection, and a summary of 266 participants recruited to date. The national outreach of the clinics is a strength; the heart of the Dementia Prevention Research Clinics are its people.